الفهرس 
Contents
Aim of the workOnly 14 pages are availabe for public view
 |  | from | 105 |  |  |
| | | from | 105 | | |
Abstract
Endometrial hyperplasia and carcinoma can be viewed as points on a continuum, including simple, complex, atypical hyperplasia and eventually adenocarcinoma. Endometrial adenocarcinoma represents 60–80% of malignant endometrial tumors. In general, the onset and development of cancer has been linked to a decrease in the rate of apoptosis. Bax protein enhances the apoptotic stimuli, leading cancer cells to apoptosis and overexpression of this protein may inhibit the progression of malignant tumors. In this work, we evaluated the expression of Bax protein in normal, hyperplastic and neoplastic endometrial tissues and investigate the association of Bax expression with clinico-pathological parameters. Eighty three cases including 7 cases of normal endometrial changes, 37 cases of endometrial hyperplasia and 39 cases of endometrial adenocarcinoma were enrolled for this study. The expression of Bax, ER and PR was evaluated by immunohistochemistry using streptavidin-biotin technique. There was a significant reduction of Bax expression in malignant endometrial cases compared to non-malignant endometrial cases (Mann Whitney, p=0.039). There was no significant association between Bax expression and histological subtypes, stage, grade and depth of invasion of endometrial carcinoma. Neither ER nor PR expression was associated with Bax expression in endometrial carcinoma, which implies that Bax expression is not controlled by hormonal stimulation. According to these result, we believe that reduced Bax expression could enhance progression.